Rituximab alone as induction therapy for membranous lupus nephritis

Medicine (United States)

Volumn 96, Issue 27, 2017, Pages

  Chavarot, Nathalie ^a   Verhelst, David ^b   Pardon, Agathe ^c   Caudwell, Valérie ^c   Mercadal, Lucile ^d   Sacchi, Antoinette ^e   Leonardi, Catherine ^f   Le Guern, Véronique ^g   Karras, Alexandre ^h   Daugas, Eric ^a  

^a BICHAT HOSPITAL   (France)

^b CENTRE HOSPITALIER D AVIGNON   (France)

^c CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e Hôpital François Quesnay   (France)

^f Department of Nephrology   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

induction therapy; lupus nephritis; monotherapy; pure class V lupus nephritis; rituximab; systemic lupus erythematosus

Indexed keywords

ALBUMIN; CORTICOSTEROID DERIVATIVE; CREATININE; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; STEROID; IMMUNOLOGIC FACTOR;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; PREMEDICATION; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SORE THROAT; TREATMENT FAILURE; YOUNG ADULT; BLOOD; CLINICAL TRIAL; LUPUS NEPHRITIS; MULTICENTER STUDY; PATHOLOGY; TREATMENT OUTCOME;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROTEINURIA; RETROSPECTIVE STUDIES; RITUXIMAB; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85022023275     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000007429     Document Type: Article

References (30)

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10:413-24.
2. Hanly JG, O'Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology (Oxford) 2016;55:252-62.
3. Baldwin DS, Gluck MC, Lowenstein J, et al. Lupus nephritis. Clinical course as related to morphologic forms and their transitions. Am J Med 1977;62:12-30.
4. Mok CC. Membranous nephropathy in systemic lupus erythematosus: A therapeutic enigma. Nat Rev Nephrol 2009;5:212-20.
5. Mercadal L, Montcel ST, Nochy D, et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 2002;17:1771-8.
6. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999;92:211-8.
7. Pasquali S, Banfi G, Zucchelli A, et al. Lupus membranous nephropathy: Long-term outcome. Clin Nephrol 1993;39:175-82.
8. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771-82.
9. Radhakrishnan J, Cattran DC. The KDiGO practice guideline on glomerulonephritis: Reading between the (guide)lines-application to the individual patient. Kidney Int 2012;82:840-56.
10. Austin HA3rd, Illei GG, Braun MJ, et al. Randomized, controlled trial of prednisone, cyclophosphamide, cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009;20:901-11.
11. Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010;77:152-60.
12. Mok CC, Ying KY, Yim CW, et al. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus 2009;18:1091-5.
13. Radhakrishnan J, Kunis CL, D'Agati V, et al. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994;42:147-54.
14. Donadio JVJr, Burgess JH, Holley KE. Membranous lupus nephropathy: A clinicopathologic study. Medicine (Baltimore) 1977;56:527-36.
15. Gonzalez-Dettoni H, Tron F. Membranous glomerulopathy in systemic lupus erythematosus. Adv Nephrol Necker Hosp 1985;14:347-64.
16. Remuzzi G, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy. Lancet 2002;360:923-4.
17. Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up. J Am Soc Nephrol 2017;28:348-58.
18. Condon MB, Ashby D, Pepper RJ, et al. Prospective observational singlecentre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab andmycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6.
19. Melander C, Sallee M, Trolliet P, et al. Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009;4:579-87.
20. Catapano F, Chaudhry AN, Jones RB, et al. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant 2010;25:3586-92.
21. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010;62: 2458-66.
22. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
23. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521-30.
24. Gregersen JW, Jayne DR. B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol 2012;8:505-14.
25. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999;26(5 suppl 14):66-73.
26. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
27. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26.
28. Diaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev 2012;11:357-64.
29. Kasitanon N, Fine DM, Haas M, et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006;15:366-70.
30. Kasitanon N, Petri M, Haas M, et al. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: A retrospective study of 29 cases. Lupus 2008;17:40-5.